Abivax SA Sponsored ADR (ABVX) has released an update.
Abivax SA reports a significant increase in its first-half 2024 operating loss to EUR 80.0M, driven by higher research and development costs for its Ulcerative Colitis clinical program and an expansion of personnel. Despite a EUR 4.5M rise in operating income, the company’s net loss grew by EUR 29.6M, and its cash position decreased to EUR 222.3M, with a cash runway extending into Q4 2025. The financials reflect the company’s strategic investments in its clinical trials and preparations for the future commercialization in the U.S.
For further insights into ABVX stock, check out TipRanks’ Stock Analysis page.
